Q2 EPS Forecast for Anavex Life Sciences Raised by Analyst

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Research analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for shares of Anavex Life Sciences in a report released on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.16) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.69) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03.

Separately, D. Boral Capital restated a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, February 12th.

Anavex Life Sciences Trading Down 0.5 %

Shares of NASDAQ:AVXL opened at $8.68 on Thursday. The stock has a fifty day simple moving average of $9.97 and a two-hundred day simple moving average of $7.77. The stock has a market capitalization of $738.32 million, a price-to-earnings ratio of -15.78 and a beta of 0.69. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44.

Institutional Investors Weigh In On Anavex Life Sciences

A number of hedge funds have recently made changes to their positions in AVXL. Geode Capital Management LLC raised its holdings in shares of Anavex Life Sciences by 2.8% in the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after buying an additional 51,946 shares during the period. Nwam LLC boosted its position in Anavex Life Sciences by 0.3% during the 4th quarter. Nwam LLC now owns 913,051 shares of the biotechnology company’s stock valued at $9,806,000 after acquiring an additional 2,575 shares in the last quarter. Northern Trust Corp boosted its position in Anavex Life Sciences by 1.6% during the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company’s stock valued at $7,592,000 after acquiring an additional 10,938 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Anavex Life Sciences by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company’s stock valued at $7,273,000 after acquiring an additional 11,239 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Anavex Life Sciences by 2,419.8% during the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company’s stock valued at $6,606,000 after acquiring an additional 590,639 shares in the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.